A Million Paracetamol Packs from Darnitsa

1 million packs of Paracetamol-Darnitsa will come to Ukrainian pharmacies in March. Darnitsa Pharmaceutical Company announces changes in production plans to ensure the first-priority supply of the population with antiviral drugs and antipyretics.

Paracetamol-Darnitsa is available in the form of tablets, with the dosage of 200 mg and 500 mg, marketing authorizations UA 4369/01/01 and 4369/01/03. The drug has antipyretic and moderate analgesic effect.

Paracetamol is on the list of medicines used to provide medical care to patients with the coronavirus infection. The drug has been recommended by the World Health Organization and the European Medical Association for fever management and pain neutralization in patients with COVID-19.

Dmytro Shymkiv, Chairman of the Supervisory Board of Darnitsa Group:

“The pandemic is a challenge and can only be countered by being proactive. That's what Darnitsa does. We have changed our priorities in favor of the production of antiviral and antipyretic drugs. By the end of March, 1 million packs of Paracetamol-Darnitsa will be produced. In the coming months, Darnitsa is ready to meet the demand for this drug. We continue to work and give confidence to Ukrainians in the access to effective and safe medicines.”

The site where Paracetamol-Darnitsa is manufactured complies with international standards of good manufacturing practice (GMP).

Darnitsa Pharmaceutical Company exercises stage-by-stage control of everything that has an impact on the quality of Paracetamol-Darnitsa - raw materials, intermediates for preparing tablets, finished products and materials used for packaging.